Loading

Please wait...

Pomalyst

Generic Name: pomalidomide (pom a LID oh mide)
Brand Names: Pomalyst
Pomalyst (pomalidomide) is used to treat multiple myeloma (cancer resulting from a progressive blood disease). Includes Pomalyst side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Pomalyst

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Pomalyst (pomalidomide) affects the immune system. It promotes immune responses to help slow tumor growth. Pomalyst is used to treat multiple myeloma (cancer resulting from a progressive blood disease). It is usually given after at least two other medications have been tried without success. Pomalyst is available only from a certified pharmacy under a special program. You must be registered in the program and agree to use birth control measures as required. Use birth control to prevent pregnancy, whether you are a man or a woman. For women: Use two forms of birth control beginning 4 weeks before you start taking Pomalyst and ending 4 weeks after you stop taking it. For men: Use a condom to prevent pregnancy during your treatment, and for up to 28 days after your treatment ends. Learn more

Pomalyst Side Effects

Pomalyst Side Effects

Note: This document contains side effect information about pomalidomide. Some of the dosage forms listed on this page may not apply to the brand name Pomalyst.

In Summary

Common side effects of Pomalyst include: anemia, anxiety, confusion, dizziness, neuropathy, neutropenia, peripheral neuropathy, and thrombocytopenia. Other side effects include: acute myocardial infarction, cerebrovascular accident, and febrile neutropenia. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to pomalidomide: oral capsule

Warning

Oral route (Capsule)

Pomalidomide is contraindicated in pregnancy. Pomalidomide is a thalidomide analogue, and thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death. In females who can become pregnant, obtain 2 negative pregnancy test before treatment initiation. It is required that females of reproductive potential use 2 forms of contraception or abstain from heterosexual sex during and for 4 weeks after stopping treatment with pomalidomide. The only way to acquire pomalidomide is through a restricted distribution program called POMALYST REMS. DVT, pulmonary embolism, myocardial infarction, and stroke have been reported in patients with multiple myeloma treated with pomalidomide. Thromboprophylaxis is recommended, and the regimen choice should be based on assessment of the underlying risk factors of the patient.

Along with its needed effects, pomalidomide (the active ingredient contained in Pomalyst) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pomalidomide:

More common

  • Black, tarry stools
  • bladder pain
  • bleeding gums
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • blood in the urine or stools
  • bloody nose
  • body aches or pain
  • burning, numbness, tingling, or painful sensations
  • chest pain
  • chills
  • cloudy urine
  • confusion
  • constipation
  • cough
  • decreased or increased urination
  • difficult, burning, or painful urination
  • difficulty with breathing
  • discouragement
  • dizziness
  • dry mouth
  • ear congestion
  • fast or irregular heartbeat
  • feeling sad or empty
  • fever
  • frequent urge to urinate
  • headache
  • incoherent speech
  • increased thirst
  • irritability
  • lack of appetite
  • loss of appetite
  • loss of interest or pleasure
  • loss of voice
  • lower back or side pain
  • metallic taste
  • muscle pain or cramps
  • muscle weakness
  • nasal congestion
  • nausea
  • numbness or tingling in the hands, feet, or lips
  • pain
  • pale skin
  • pinpoint red spots on the skin
  • rapid weight gain
  • runny nose
  • shakiness in the legs, arms, hands, or feet
  • sneezing
  • sore throat
  • stomach pain
  • tightness in the chest
  • trembling or shaking of the hands or feet
  • trouble concentrating
  • trouble sleeping
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • unusual weight gain or loss
  • vomiting
  • weakness in the arms, hands, legs, or feet

Less common

  • Anxiety
  • dizziness or lightheadedness
  • fainting
  • pain, redness, or swelling in the arm or leg
  • troubled breathing

Incidence not known

  • Blistering, peeling, or loosening of the skin
  • diarrhea
  • difficulty in passing urine (dribbling)
  • itching
  • joint pain
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • unusual tiredness or weakness
  • weakness or heaviness of the legs
  • yellow eyes or skin

Some side effects of pomalidomide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Back pain
  • blurred vision
  • decreased appetite
  • difficulty with moving
  • flushed, dry skin
  • fruit-like breath odor
  • increased hunger
  • increased sweating
  • lack or loss of strength
  • muscle spasms or stiffness
  • night sweats
  • rash

Incidence not known

  • Feeling of constant movement of self or surroundings
  • sensation of spinning

For Healthcare Professionals

Applies to pomalidomide: oral capsule

Cardiovascular

Common (1% to 10%): Deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, cardiac failure

Frequency not reported: Atrial fibrillation, angina pectoris, congestive cardiac failure, hypotension

Hematologic

Very common (10% or more): Neutropenia (53%), anemia (46%), thrombocytopenia (27%), leukopenia (20%), lymphopenia (15%)

Common (1% to 10%): Febrile neutropenia, neutropenic sepsis, decreased neutrophil count, decreased white blood cell count, decreased platelet count, pancytopenia

Frequency not reported: Decreased lymphocyte count, septic shock, decreased hemoglobin

Hepatic

Common (1% to 10%): Increased ALT

Uncommon (0.1% to 1%): Hepatitis, hyperbilirubinemia

Frequency not reported: Increased AST

Postmarketing reports: Hepatic failure

Hypersensitivity

Postmarketing reports: Allergic reactions (e.g., angioedema, urticaria)

Nervous system

Very common (10% or more): Dizziness (22%), peripheral neuropathy (22%), neuropathy (18%), headache (15%), tremor (13%), confusional state (13%)

Common (1% to 10%): Depressed level of consciousness, vertigo

Frequency not reported: Syncope

Oncologic

Frequency not reported: Second primary malignancies (e.g., acute myelogenous leukemia)

Postmarketing reports: Tumor lysis syndrome

Respiratory

Very common (10% or more): Dyspnea (45%), upper respiratory tract infection (37%), pneumonia (34%), cough (22%), epistaxis (17%), productive cough (13%), oropharyngeal pain (11%)

Common (1% to 10%): Interstitial lung disease, bronchopneumonia, bronchitis, nasopharyngitis, epistaxis

Frequency not reported: Pneumonitis, chronic obstructive pulmonary disease, pneumocystis jiroveci pneumonia, respiratory syncytial viral, pneumonia streptococcal, lobar pneumonia, lung infection, respiratory failure, bronchospasm

Dermatologic

Very common (10% or more): Rash (21%), hyperhidrosis (16%), pruritus (15%), night sweats (13%), dry skin (11%)

Frequency not reported: Cellulitis

Gastrointestinal

Very common (10% or more): Constipation (37%), nausea (36%), diarrhea (36%), vomiting (14%)

Very rare (less than 0.01%): Clostridium difficile colitis

Frequency not reported: Abdominal pain

Genitourinary

Very common (10% or more): Urinary tract infection (17%)

Common (1% to 10%): Urinary retention, pelvic pain

Frequency not reported: Urosepsis

Metabolic

Very common (10% or more): Decreased appetite (23%), hypercalcemia (22%), hyperglycemia (15%), decreased weight (15%), hyponatremia (13%), hypokalemia (12%), hypocalcemia (12%), increased weight (11%)

Common (1% to 10%): Dehydration, hyperkalemia

Frequency not reported: Failure to thrive

Musculoskeletal

Very common (10% or more): Back pain (35%), musculoskeletal chest pain (23%), muscle spasms (22%), bone pain (18%), arthralgia (17%), muscular weakness (14%), musculoskeletal pain (12%)

Common (1% to 10%): Extremity pain

Frequency not reported: Femur fracture, fall, compression fracture, spinal compression fracture

Psychiatric

Very common (10% or more): Insomnia (16%), anxiety (13%)

Frequency not reported: Mental status change

Renal

Very common (10% or more): Increased blood creatinine (19%), renal failure (15%)

Other

Very common (10% or more): Fatigue and asthenia (63%), pyrexia (32%), peripheral edema (25%), chills (13%)

Frequency not reported: Pain, general physical health deterioration, non-cardiac chest pain, multi-organ failure, viral infection

Immunologic

Very common (10% or more): Infection (55%)

Common (1% to 10%): Sepsis

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Pomalyst (www.drugs.com/pomalyst.html).